Artificial Intelligence (AI) Cytopathology Trial

Recruiting now

Conditions studied: Pancreatic Solid Lesions

In brief

Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs using standard of care. Sample slides are prepared by a cytopathologist at bedside and observed under a microscope. At the same time, the slides are scanned using a slide scanner and those images are saved for interpretation by AI at a later time.

Key facts

Study ID

NCT05018663

Run by

The University of Texas Health Science Center, Houston

People needed

50

Starts

2021-07-21

Expected to finish

2028-01-30

Last updated by the study team

2023-02-16

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have EUS finding of a PSL;
• Do not have contraindications for FNA/FNB.

You may not qualify if…

• Inability to provide informed consent for the procedure;
• Contraindication for FNA/FNB eg coagulopathy, lack of avascular window for FNA.

Where it is running

• Memorial Hermann Hospital — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.